Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.

Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.

The use of tyrosine kinase inhibitors (TKIs) against EGFR/c-Met in non-small cell lung cancer (NSCLC) has been shown to be effective in increasing patient progression free survival (PFS), but their efficacy is limited due to the development of resistance and tumor recurrence. Therefore, understandin...

Full description

Bibliographic Details
Main Authors:	Jason T Fong, Ryan J Jacobs, David N Moravec, Srijayaprakash B Uppada, Gregory M Botting, Marie Nlend, Neelu Puri
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3817236?pdf=render

Similar Items

Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
by: Gregory M Botting, et al.
Published: (2015-01-01)

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
by: Shigeki Nanjo, et al.
Published: (2013-01-01)

Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
by: Wanhong Xu, et al.
Published: (2019-01-01)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
by: Qiming Wang, et al.
Published: (2019-06-01)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.
by: Elena Ortiz-Zapater, et al.
Published: (2017-01-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019-11-01)

AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
by: Yun Jung Choi, et al.
Published: (2015-01-01)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
by: Dario Presutti, et al.
Published: (2015-01-01)

MET-EGFR dimerisation in lung adenocarcinoma is dependent on EGFR mutations and altered by MET kinase inhibition
by: Lee, Richard William
Published: (2017)

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
by: Maicol Mancini, et al.
Published: (2018-02-01)

Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma
by: Amelio, A.L, et al.
Published: (2021)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
by: Miyoshi S, et al.
Published: (2015-04-01)

EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer
by: Zachary D Crees, et al.
Published: (2020-09-01)

Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
by: Aleksandra Simiczyjew, et al.
Published: (2019-10-01)

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
by: Jana Fassunke, et al.
Published: (2018-11-01)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling
by: Evan K. Day, et al.
Published: (2020-03-01)

The Developments of Dual EGFR and c-Met Kinase Inhibitors and DBPR104 Phosphate Prodrugs
by: Kuo, Po-Hsien, et al.
Published: (2018)

Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Yanxia Li, et al.
Published: (2016-11-01)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014-01-01)

Exploitation and Mechanistic Validation of Drug-combination Strategies to Overcome EGFR-inhibitor resistance in NSCLC cells
by: Wang, Yu-Chieh
Published: (2008)

Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
by: Ewelina Dratkiewicz, et al.
Published: (2019-12-01)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
by: Rossella Bruno, et al.
Published: (2021-06-01)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
by: Aleksandra Simiczyjew, et al.
Published: (2018-09-01)

MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription
by: Liang Deng, et al.
Published: (2021-08-01)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
by: Qiong Qin, et al.
Published: (2020-09-01)

Knockdown of the fat mass and obesity gene disrupts cellular energy balance in a cell-type specific manner.
by: Ryan T Pitman, et al.
Published: (2012-01-01)

MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance.
by: Chang Gong Lee, et al.
Published: (2014-01-01)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
by: Ken Uchibori, et al.
Published: (2017-03-01)

Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
by: Sangah Lee, et al.
Published: (2021-06-01)

Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
by: Yoojung Kwon, et al.
Published: (2019-09-01)

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
by: Tao Zhang, et al.
Published: (2020-05-01)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
by: Xuejiao Liu, et al.
Published: (2019-05-01)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
by: Andrew J. Piper-Vallillo, MD, et al.
Published: (2020-11-01)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
by: Sho Watanabe, et al.
Published: (2021-03-01)

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
by: Xuexia Tong, et al.
Published: (2019-12-01)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
by: Pedro E.N.S. Vasconcelos, MS, et al.
Published: (2021-03-01)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
by: Chen Zhang, et al.
Published: (2021-10-01)

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
by: Tao Zhang, et al.
Published: (2021-08-01)